Gyre Therapeutics (GYRE) EBT Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.25% |
| Dec 31, 2025 | -0.15% |
| Sep 30, 2025 | 19.88% |
| Jun 30, 2025 | 16.32% |
| Mar 31, 2025 | 24.40% |
| Dec 31, 2024 | -9.44% |
| Sep 30, 2024 | 18.22% |
| Jun 30, 2024 | 19.51% |
| Mar 31, 2024 | 23.11% |
| Dec 31, 2023 | -49.97% |
| Sep 30, 2023 | 28.14% |
| Jun 30, 2023 | 23.72% |
| Mar 31, 2023 | 26.53% |
| Dec 31, 2022 | -30.76% |
| Sep 30, 2022 | 3.36% |
| Jun 30, 2022 | 60.84% |
| Mar 31, 2022 | -28.57% |
| Dec 31, 2021 | -40.19% |
| Sep 30, 2021 | -39.52% |
| Jun 30, 2021 | -32.72% |
| Mar 31, 2021 | -44.23% |
| Dec 31, 2020 | -24.60% |
| Sep 30, 2020 | -34.73% |
| Jun 30, 2020 | -31.80% |
| Mar 31, 2020 | 6.80% |
| Dec 31, 2019 | -24.02% |
| Sep 30, 2019 | -21.25% |
| Jun 30, 2019 | -11.24% |
| Mar 31, 2019 | -5.42% |
| Dec 31, 2018 | 0.21% |
| Sep 30, 2018 | 9.82% |
| Jun 30, 2018 | 12.04% |
| Mar 31, 2018 | 8.97% |
| Dec 31, 2017 | 17.94% |
| Sep 30, 2017 | 5.97% |
| Jun 30, 2017 | -19.20% |
| Mar 31, 2017 | -30.82% |
| Dec 31, 2016 | 17.49% |
| Sep 30, 2016 | 12.03% |
| Jun 30, 2016 | -16.45% |
| Mar 31, 2016 | -17.98% |
| Dec 31, 2015 | -44.50% |
| Sep 30, 2015 | -27.10% |
| Jun 30, 2015 | -23.03% |